Who Generates Higher Gross Profit? United Therapeutics Corporation or Travere Therapeutics, Inc.

United Therapeutics leads in gross profit over Travere Therapeutics.

__timestampTravere Therapeutics, Inc.United Therapeutics Corporation
Wednesday, January 1, 2014276322261162636000
Thursday, January 1, 2015977070001396725000
Friday, January 1, 20161290370001526100000
Sunday, January 1, 20171513320001619600000
Monday, January 1, 20181587190001429100000
Tuesday, January 1, 20191701040001331200000
Wednesday, January 1, 20201921950001375200000
Friday, January 1, 20212207060001563000000
Saturday, January 1, 20222044260001789600000
Sunday, January 1, 20231337880002070000000
Loading chart...

Data in motion

A Tale of Two Therapeutics: Gross Profit Analysis

In the competitive landscape of the pharmaceutical industry, understanding which companies are leading in profitability is crucial. Over the past decade, United Therapeutics Corporation has consistently outperformed Travere Therapeutics, Inc. in terms of gross profit. From 2014 to 2023, United Therapeutics' gross profit has shown a robust upward trend, peaking at approximately $2.07 billion in 2023. In contrast, Travere Therapeutics, Inc. reached its highest gross profit in 2021, with around $220 million, which is roughly 10% of United Therapeutics' peak.

This stark difference highlights United Therapeutics' dominant position, with its gross profit being nearly 10 times higher than Travere's on average. The data underscores the importance of strategic positioning and market presence in achieving financial success in the pharmaceutical sector. As the industry evolves, these insights provide a valuable benchmark for investors and stakeholders alike.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025